ZIONSVILLE, Ind. (February 29, 2024) – Rahal Letterman Lanigan Racing (RLL) announced today that Patients Choice Laboratories (PCL) has renewed their partnership with the team as the “Official Laboratory Partner” and associate sponsor of the No. 15 NTT INDYCAR SERIES entry for Graham Rahal, in a multi-year deal. PCL provides advanced laboratory testing specializing in molecular and toxicology diagnostics that provide precise and specific results allowing for quick diagnoses and treatment of patients. PCL performs testing in the areas of infectious diseases, including COVID-19, pharmacogenetics, and toxicology.
“Patients Choice Laboratories provides industry-leading diagnostic services and continues to grow their business at an impressive pace,” said Bobby Rahal, co-owner of Rahal Letterman Lanigan Racing with David Letterman and Mike Lanigan. “We are proud to partner with a company that does such important work in the medical industry and are excited to extend our partnership.”
“We are proud and excited to be continuing our partnership with RLL, a first-class organization that is rich in tradition and where excellence is achieved in innovation, speed and precision which are traits that we at PCL hold in high regard,” said Brad Moss, president of PCL. “We are thrilled to continue working with the great partners within the RLL and INDYCAR ecosystems, and bring our expertise in medical diagnostics to help providers and patients make better treatment decisions.”
The 2024 NTT INDYCAR SERIES season opens Sunday, March 10 on the Streets of St. Petersburg, Florida, for the 20th Firestone Grand Prix of St. Petersburg. North America’s premier open-wheel series will crisscross the United States, including a stop for the 108th Indianapolis 500 on Sunday, May 26, before culminating in Nashville for the championship finale Sunday, Sept. 15. All on-track action can be seen on NBC or NBC’s Peacock Premium streaming service or USA Network. For more information about the series or team, visit www.indycar.com and www.rahal.com.
About Patients Choice Laboratories
Patients Choice Laboratories (PCL), a CLIA certified and CAP accredited laboratory based in Indianapolis, Indiana, is a leading provider of comprehensive laboratory testing throughout the United States. Since 2013 PCL has served patients and providers with a focus on fast, accurate, and reliable results. Utilizing innovative molecular technology, PCL provides specific results allowing for quick diagnoses and treatment of patients. PCL can provide treatment recommendations based on antibiotic-resistant genes to improve antimicrobial stewardship and patient outcomes. PCL is at the forefront of infectious diseases, clinical labs, pharmacogenetics, and toxicology to ensure the health of our communities now and into the future. Learn more about how we are pioneering new ways to provide patient care on our website: pclabsdx.com.